Sparks - BioVersys

BioVersys has reported its H126 results, highlighting continued clinical momentum across its lead programmes and an upgraded near-term financial outlook. Operating income increased to CHF2.0m (including a CHF0.8m payment from Shionogi under the July 2025 collaboration agreement), while R&D investment rose to CHF13.6m (vs CHF6.2m in H125) as BV100 advanced through pivotal development; the cash position remained robust at CHF69.3m. Crucially, management has upgraded its FY26 guidance, narrowing the expected operating loss to CHF32–34m (CHF40–45m previously) and lifting year-end cash guidance to CHF53m, preserving runway into 2028 and through the pivotal BV100 readout. We understand the guidance upgrade largely reflects the phasing of certain R&D expenditure into later periods, consistent with modest shifts in trial timing rather than a lower overall development spend.

The slight clinical timing changes appear manageable, in our opinion. The Phase IIb RIV-CARE site initiation is now planned for September, with interim data in H127 (end-FY26 previously); enrolment of Chinese sites into the pivotal Phase III RIV-TARGET study is expected from March 2027, while alpibectir’s tuberculosis meningitis study is targeting first-patient, first-visit in Q426 (Q226 previously). Importantly, the core value-driving milestones remain broadly intact, including end-2027 RIV-TARGET enrolment completion and top-line data in early 2028.